|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
These targeted multifunctional LCP NPs more efficiently accumulated in the tumor tissue.
|
31195300 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The tumor/blood and tumor/muscle ratios at 30 min were 0.63 and 1.77, respectively, indicating that the [<sup>125</sup>I]I-LCP accumulation in tumors was inadequate for in vivo imaging.
|
31445852 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
The efficient delivery of VEGF siRNA by L4-LCP NPs that resulted in significant tumor regression indicates that phenyl galactoside could be a promising HCC-targeting ligand for therapeutic siRNA delivery to treat liver cancer.
|
29808997 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that the targeted LCP is a promising vector to deliver pooled siRNA into tumors and to achieve multiple target blocking.
|
22686936 |
2012 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, the well-devised multifunctional LCP NPs are one of the most promising delivery systems for combined and targeted cancer therapy.
|
31195300 |
2019 |
|
Gingivitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fifty-five participants with generalized chronic periodontitis (GCP group, n: 21), with localized chronic periodontitis (LCP group, n: 19) and with gingivitis or healthy (control group, n: 15) subjects were treated and followed up for 6 months.
|
30187981 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, the well-devised multifunctional LCP NPs are one of the most promising delivery systems for combined and targeted cancer therapy.
|
31195300 |
2019 |
|
Mammary Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, biocompatible multifunctional lipid-coated calcium phosphate nanoparticles (LCP NPs) were designed and constructed as an efficient targeted delivery system for combined gene/photothermal therapy to inhibit growth of the triple negative breast tumor (MDA-MB-468) in vitro and in vivo.
|
31195300 |
2019 |
|
Localized chronic periodontitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Fifty-five participants with generalized chronic periodontitis (GCP group, n: 21), with localized chronic periodontitis (LCP group, n: 19) and with gingivitis or healthy (control group, n: 15) subjects were treated and followed up for 6 months.
|
30187981 |
2019 |
|
Generalized chronic periodontitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Fifty-five participants with generalized chronic periodontitis (GCP group, n: 21), with localized chronic periodontitis (LCP group, n: 19) and with gingivitis or healthy (control group, n: 15) subjects were treated and followed up for 6 months.
|
30187981 |
2019 |
|
Presenile dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, the LCP does not match the context of dementia care in the nursing home.
|
28693652 |
2018 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, using LCP NPs to deliver the BRAF peptide vaccine is a promising strategy for the BRAF-mutant melanoma therapy.
|
29094184 |
2018 |
|
Tuberculosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In Mycobacterium tuberculosis complex (Mtbc) strains, the causative agents of tuberculosis (TB), the genes Rv3484 and Rv3267 encode for LCP proteins which are putatively involved in arabinogalactan transfer to peptidoglycan.
|
29500450 |
2018 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The efficient delivery of VEGF siRNA by L4-LCP NPs that resulted in significant tumor regression indicates that phenyl galactoside could be a promising HCC-targeting ligand for therapeutic siRNA delivery to treat liver cancer.
|
29808997 |
2018 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The efficient delivery of VEGF siRNA by L4-LCP NPs that resulted in significant tumor regression indicates that phenyl galactoside could be a promising HCC-targeting ligand for therapeutic siRNA delivery to treat liver cancer.
|
29808997 |
2018 |
|
Malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
The efficient delivery of VEGF siRNA by L4-LCP NPs that resulted in significant tumor regression indicates that phenyl galactoside could be a promising HCC-targeting ligand for therapeutic siRNA delivery to treat liver cancer.
|
29808997 |
2018 |
|
Dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, the LCP does not match the context of dementia care in the nursing home.
|
28693652 |
2018 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
VEGF siRNAs delivered by L4-LCP NPs downregulated VEGF expression in HCC in vitro and in vivo and led to a potent antiangiogenic effect in the tumor microenvironment of a murine orthotopic HCC model.
|
29808997 |
2018 |
|
Muscle Rigidity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Compared with LCP group, (1) EF-tibia group showed significantly lower (p < 0.001) compression stiffness and torsional rigidity; (2) EF-femur group showed significantly lower (p < 0.001) compression stiffness, but significantly higher (p < 0.001) torsional rigidity.
|
28103852 |
2017 |